Research programme: TT 223 + CD26 antigen antagonists - Transition Therapeutics

Drug Profile

Research programme: TT 223 + CD26 antigen antagonists - Transition Therapeutics

Alternative Names: G1 + CD26 antigen antagonists; TT 223 + CD26 antigen antagonists; TT-223 + DPP-IV inhibitors

Latest Information Update: 20 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transition Therapeutics
  • Class Antihyperglycaemics; Carrier proteins; CD antigens; Gastrointestinal hormones; Hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action CD26 antigen inhibitors; Gastrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 20 May 2008 Discontinued - Preclinical for Diabetes mellitus in Canada (Injection/PO combination)
  • 14 Mar 2008 Transition Therapeutics and Eli Lilly enter into a licensing and collaboration agreement for gastrin-based therapies in Diabetes
  • 06 Jul 2007 Preclinical trials in Diabetes mellitus in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top